Aspergillus, angiogenesis, and obesity: The story behind beloranib

Journal of Psychosocial Nursing and Mental Health Services

Volumn 53, Issue 3, 2015, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTIOBESITY AGENT; CINNAMIC ACID DERIVATIVE; CKD732; CYCLOHEXANE DERIVATIVE; EPOXIDE; FUMAGILLIN; SESQUITERPENE; UNSATURATED FATTY ACID;

ANIMAL; ASPERGILLUS; HUMAN; MOUSE; OBESITY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTI-OBESITY AGENTS; ASPERGILLUS; CINNAMATES; CYCLOHEXANES; EPOXY COMPOUNDS; FATTY ACIDS, UNSATURATED; HUMANS; MICE; OBESITY; SESQUITERPENES;

EID: 84939640351     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20150219-01     Document Type: Article

References (18)

1. Cao, Y. (2010). Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature Reviews. Drug Discovery, 9, 107-115. doi:10.1038/nrd3055
2. Chun, E., Han, C.K., Yoon, J.H., Sim, T.B., Kim, Y.K., & Lee, K.Y. (2005). Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Interna tional Journal of Cancer, 114, 124-130
3. D’Amato, R.J., Loughnan, M.S., Flynn, E., & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy Sciences of the United States of America, 91, 4082-4085
4. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285, 1182-1186
5. Han, C.K., Ahn, S.K., Choi, N.S., Hong, R.K., Moon, S.K., Chun, H.S., No, K.T. (2000). Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2 Bioorganic and Medicinal Chemistry Letters, 10, 39-43
6. Hanson, F.R., & Eble, T.E. (1949). An antiphage agent isolated from Aspergillus sp. Journal of Bacteriology, 58, 527-529
7. Hughes, T.E., Kim, D.D., Marjason, J., Proietto, J., Whitehead, J.P., & Vath, J.E. (2013). Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity, 21, 1782-1788
8. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 348, 555-557
9. Joharapurkar, A.A., Dhanesha, N.A., & Jain, M.R. (2014). Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes, Metabolic Syndrome, and Obesity: Targets and Therapy, 7, 73-84. doi:10.2147/DMSO.S56924
10. Killough, J.H., Magill, G.B., & Smith, R.C. (1952). The treatment of amebiasis with fumagillin. Science, 115, 71-72
11. Kim, E.J., & Shin, W.H. (2005). General pharmacology of CKD-732, a new anticancer agent: Effects on central nervous, cardiovascular, and respiratory system. Biological and Pharmaceutical Bulletin, 28, 217-223
12. Kim, Y.M., An, J.J., Jin, Y.J., Rhee, Y., Cha, B.S., Lee, H.C., & Lim, S.K. (2007). Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732 Journal of Molecular Endocrinology, 38, 455-465
13. Lijnen, H.R., Frederix, L., & Van Hoef, B. (2010). Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity. Obesity, 18, 2241-2246. doi:10.1038/oby.2009.503
14. Rupnick, M.A., Panigrahy, D., Zhang, C.Y., Dallabrida, S.M., Lowell, B.B., Langer, R., & Folkman, M.J. (2002). Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences of the United States of America, 99, 10730-10735
15. Satchi-Fainaro, R., Puder, M., Davies, J.W., Tran, H.T., Sampson, D.A., Greene, A.K., Folkman, J. (2004). Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 Nature Medicine, 10, 255-261
16. Shin, S.J., Ahn, J.B., Park, K.S., Lee, Y.J., Hong, Y.S., Kim, T.W., Chung, H.C. (2012). A phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational New Drugs, 30, 672-680. doi:10.1007/s10637-010-9625-x
17. Shin, S.J., Jeung, H.C., Ahn, J.B., Rha, S.Y., Roh, J.K., Park, K.S., Chung, H.C. (2010). A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs, 28, 650-658. doi:10.1007/s10637-009-9287-8
18. Walker, E.R., McGee, R.E., & Druss, B.G. (2015). Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry. Advance online publication. doi:10.1001/jamapsychiatry.2014.2502